JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Neutral 49.7%

Neg 0% Neu 49.7% Pos 0%

JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.